TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06382051: A Multicenter, Prospective, Study to Evaluate the Impact of Modifying the Validated Psoriasis Epidemiology Screening Tool (PEST) on the Potential Diagnosis of Psoriatic Arthritis in Adult Patients With Moderate-to-severe

Sponsor: Novartis Pharmaceuticals · Phase: PHASE2 · Area: DERMATOLOGY_AESTHETIC · Target Enrollment: 502 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$4,102,200

Rescue Site Savings

+$2,709,000

Unlock Full NCT06382051 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06382051 Rescue Dossier →